Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma

NCT00006100 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

BIOLOGICAL: aldesleukin
BIOLOGICAL: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes
DRUG: fludarabine phosphate
PROCEDURE: peripheral blood stem cell transplantation

Sponsor

Milton S. Hershey Medical Center

Collaborators

[object Object]